Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2016

Gremel G, Lee R J, Girotti M R, Mandal A K, Valpione S, Garner G, Ayub M, Wood S, Rothwell D G, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R

Abstract excerpt

BACKGROUND: The application of precision medicine in oncology requires in-depth characterisation of a patient's tumours and the dynamics of their responses to treatment. PATIENTS AND METHODS: We used next-generation sequencing of circulating cell-free DNA (cfDNA) to monitor the response of a KIT p.L576P-mutant metastatic vaginal mucosal melanoma to sequential targeted, immuno- and chemotherapy. RESULTS: Despite a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to Imatinib Mesylate

Share to Melanoma

Share to Paclitaxel

Share to Precision Medicine

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 27502704
DOI: 10.1093/annonc/mdw278
PMCID: PMC5035787

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.PMID 27502704Read ↗

Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.Semantic proximity Read ↗

The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patientsSemantic proximity Read ↗

Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.Semantic proximity Read ↗

Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.Semantic proximity Read ↗

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNASemantic proximity Read ↗

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.Semantic proximity Read ↗

Longitudinal whole-exome sequencing of cell-free DNA unravels the metastatic evolutionary dynamics of <i>BRCA2</i> -mutated breast cancerSemantic proximity Read ↗

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.Semantic proximity Read ↗

Single whole genome sequencing analysis blazes the trail for precision medicine.Semantic proximity Read ↗

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.